

# Walter E Haefeli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7502868/publications.pdf>

Version: 2024-02-01

416  
papers

14,635  
citations

20817

60  
h-index

33894

99  
g-index

435  
all docs

435  
docs citations

435  
times ranked

16249  
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment of atrial fibrillation with doxapram: TASK-1 potassium channel inhibition as a novel pharmacological strategy. <i>Cardiovascular Research</i> , 2022, 118, 1728-1741.	3.8	21
2	Clomethiazole inhibits cytochrome P450 2E1 and improves alcoholic liver disease. <i>Gut</i> , 2022, 71, 842-844.	12.1	7
3	Effect of Pantoprazole on the Absorption of Hydroxychloroquine A Randomized Drug-Drug Interaction Trial in Healthy Adults. <i>Clinical Pharmacology in Drug Development</i> , 2022, 11, 285-290.	1.6	3
4	Perpetrator Characteristics of Azole Antifungal Drugs on Three Oral Factor Xa Inhibitors Administered as a Microdosed Cocktail. <i>Clinical Pharmacokinetics</i> , 2022, 61, 97-109.	3.5	8
5	Does the circulating ketoconazole metabolite N-deacetyl ketoconazole contribute to the drug-drug interaction potential of the parent compound?. <i>European Journal of Pharmaceutical Sciences</i> , 2022, 169, 106076.	4.0	5
6	Important Requirements for the Selection of Internal Standards during the Development of Desorption/Ionization Assays for Drug Quantification in Biological Matrices—A Practical Example. <i>Molecules</i> , 2022, 27, 690.	3.8	2
7	Low Exposure to Direct Oral Anticoagulants Is Associated with Ischemic Stroke and Its Severity. <i>Journal of Stroke</i> , 2022, 24, 88-97.	3.2	8
8	Predicting Hospital Readmissions from Health Insurance Claims Data: A Modeling Study Targeting Potentially Inappropriate Prescribing. <i>Methods of Information in Medicine</i> , 2022, 61, 055-060.	1.2	1
9	Approaching Sites of Action of Temozolomide for Pharmacological and Clinical Studies in Glioblastoma. <i>Biomedicines</i> , 2022, 10, 1.	3.2	17
10	Simultaneous Quantification and Pharmacokinetic Characterization of Doxapram and 2-Ketodoxapram in Porcine Plasma and Brain Tissue. <i>Pharmaceutics</i> , 2022, 14, 762.	4.5	0
11	Evaluation of CYP2C19 activity using microdosed oral omeprazole in humans. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 975-987.	1.9	3
12	Functional Characterization of the Solute Carrier LAT-1 (SLC7A5/SLC2A3) in Human Brain Capillary Endothelial Cells with Rapid UPLC-MS/MS Quantification of Intracellular Isotopically Labelled L-Leucine. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3637.	4.1	4
13	Drug Treatment of Hypercholesterolemia in Older Adults: Focus on Newer Agents. <i>Drugs and Aging</i> , 2022, 39, 251-256.	2.7	2
14	Prevalence and patient-rated relevance of complexity factors in medication regimens of community-dwelling patients with polypharmacy. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 1127-1136.	1.9	2
15	Analytical Performance Evaluation of New DESI Enhancements for Targeted Drug Quantification in Tissue Sections. <i>Pharmaceutics</i> , 2022, 15, 694.	3.8	6
16	A proof of concept phase I/II pilot trial of LSD1 inhibition by tranilcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy. <i>Leukemia</i> , 2021, 35, 701-711.	7.2	56
17	A prognostic model predicted deterioration in health-related quality of life in older patients with multimorbidity and polypharmacy. <i>Journal of Clinical Epidemiology</i> , 2021, 130, 1-12.	5.0	7
18	Absolute Bioavailability of Microdosed Midazolam After Buccal Administration Is Dependent on Buccal Exposure Time. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 472-479.	2.0	6

#	ARTICLE	IF	CITATIONS
19	Application of triple quadrupole tandem mass spectrometry to the bioanalysis of collision-induced dissociation-resistant cyclic peptides – Ultra-sensitive quantification of the somatostatin-analog pasireotide utilizing UHPLC-MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 194, 113728.	2.8	3
20	Application of Microdosed Intravenous Omeprazole to Determine Hepatic CYP2C19 Activity. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 789-798.	2.0	5
21	Pharmacoenhancement of Low Crizotinib Plasma Concentrations in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer using the CYP3A Inhibitor Cobicistat. <i>Clinical and Translational Science</i> , 2021, 14, 487-491.	3.1	9
22	Approaching sites of action of drugs in clinical pharmacology: New analytical options and their challenges. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 858-874.	2.4	9
23	Recruitment and Baseline Characteristics of Participants in the AgeWell.de Study – A Pragmatic Cluster-Randomized Controlled Lifestyle Trial against Cognitive Decline. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 408.	2.6	15
24	Rapid MALDI-MS Assays for Drug Quantification in Biological Matrices: Lessons Learned, New Developments, and Future Perspectives. <i>Molecules</i> , 2021, 26, 1281.	3.8	11
25	Differential Effect of a Continental Breakfast on Tacrolimus Formulations With Different Release Characteristics. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 899-907.	1.6	3
26	A nuclear factor kappa B reporter cell line used to evaluate ex vivo the net inflammatory effect of plasma samples from patients with rheumatoid arthritis, psoriasis, or COVID-19. <i>Cytokine</i> , 2021, 138, 155399.	3.2	2
27	Current Drug Treatment Strategies for Atrial Fibrillation and TASK-1 Inhibition as an Emerging Novel Therapy Option. <i>Frontiers in Pharmacology</i> , 2021, 12, 638445.	3.5	14
28	Low risk of the TMPRSS2 inhibitor camostat mesylate and its metabolite GBPA to act as perpetrators of drug-drug interactions. <i>Chemico-Biological Interactions</i> , 2021, 338, 109428.	4.0	1
29	Disease-dependent variations in the timing and causes of readmissions in Germany: A claims data analysis for six different conditions. <i>PLoS ONE</i> , 2021, 16, e0250298.	2.5	8
30	Desorption/Ionization-MS Methods for Drug Quantification in Biological Matrices and Their Validation Following Regulatory Guidance. <i>Analytical Chemistry</i> , 2021, 93, 7152-7163.	6.5	8
31	Intact plasma quantification of the large therapeutic lipopeptide bulevirtide. <i>Analytical and Bioanalytical Chemistry</i> , 2021, 413, 5645-5654.	3.7	4
32	Time-Resolved Effect of Interferon-Alpha 2a on Activities of Nuclear Factor Kappa B, Pregnane X Receptor and on Drug Disposition Genes. <i>Pharmaceutics</i> , 2021, 13, 808.	4.5	3
33	Bioanalysis of selinexor in mouse plasma micro-samples utilizing UPLC-MS/MS. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021, 1176, 122781.	2.3	2
34	Rapid and Sensitive Quantification of Intracellular Glycyl-Sarcosine for Semi-High-Throughput Screening for Inhibitors of PEPT-1. <i>Pharmaceutics</i> , 2021, 13, 1019.	4.5	3
35	In vitro evidence suggesting that the toll-like receptor 7 and 8 agonist resiquimod (R-848) unlikely affects drug levels of co-administered compounds. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 162, 105826.	4.0	5
36	The Acceptance of Interruptive Medication Alerts in an Electronic Decision Support System Differs between Different Alert Types. <i>Methods of Information in Medicine</i> , 2021, , .	1.2	2

#	ARTICLE	IF	CITATIONS
37	Predicting hospital admissions from individual patient data (IPD): an applied example to explore key elements driving external validity. <i>BMJ Open</i> , 2021, 11, e045572.	1.9	1
38	Estimated Thresholds of Minimum Necessary Adherence for Effective Treatment with Direct Oral Anticoagulants – A Retrospective Cohort Study in Health Insurance Claims Data. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 2209-2220.	1.8	4
39	Customization of information on adverse drug reactions according to patients’ needs – A qualitative study. <i>Patient Education and Counseling</i> , 2021, 104, 2351-2357.	2.2	3
40	Treatment with Edoxaban Attenuates Acute Stroke Severity in Mice by Reducing Blood–Brain Barrier Damage and Inflammation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9893.	4.1	6
41	Investigating the Central Nervous System Disposition of Actinomycin D: Implementation and Evaluation of Cerebral Microdialysis and Brain Tissue Measurements Supported by UPLC-MS/MS Quantification. <i>Pharmaceutics</i> , 2021, 13, 1498.	4.5	3
42	The influence of intervention complexity on barriers and facilitators in the implementation of professional pharmacy services – A systematic review. <i>Research in Social and Administrative Pharmacy</i> , 2021, 17, 1651-1662.	3.0	9
43	The impact of a computerized physician order entry system implementation on 20 different criteria of medication documentation – a before-and-after study. <i>BMC Medical Informatics and Decision Making</i> , 2021, 21, 279.	3.0	6
44	Development and Pilot-Testing of Key Questions to Identify Patients’ Difficulties in Medication Administration. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 2479-2488.	1.8	0
45	Factors That Influence Adherence to Medication in Adults With Congenital Heart Disease (ACHD). <i>Frontiers in Psychiatry</i> , 2021, 12, 788013.	2.6	10
46	Can Machine Learning from Real-World Data Support Drug Treatment Decisions? A Prediction Modeling Case for Direct Oral Anticoagulants. <i>Medical Decision Making</i> , 2021, , 0272989X2110646.	2.4	6
47	Association of mental demands in the workplace with cognitive function in older adults at increased risk for dementia. <i>BMC Geriatrics</i> , 2021, 21, 688.	2.7	1
48	Reasons for Drug Administration Problems and Perceived Needs for Assistance of Patients, Family Caregivers, and Nurses: A Qualitative Study. <i>Journal of Patient Safety</i> , 2020, 16, 149-154.	1.7	2
49	Process of translation and cross-cultural adaptation of two Australian instruments to evaluate the physician-pharmacist collaboration in Germany. <i>Research in Social and Administrative Pharmacy</i> , 2020, 16, 74-83.	3.0	5
50	Information on adverse drug reactions – Proof of principle for a structured database that allows customization of drug information. <i>International Journal of Medical Informatics</i> , 2020, 133, 103970.	3.3	6
51	Rapid drug detection in whole blood droplets using a desorption electrospray ionization static profiling approach – a proof-of-concept. <i>Rapid Communications in Mass Spectrometry</i> , 2020, 34, e8614.	1.5	11
52	Investigation of a possible association of potentially inappropriate medication for older adults and frailty in a prospective cohort study from Germany. <i>Age and Ageing</i> , 2020, 49, 20-25.	1.6	27
53	IL411 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression. <i>Cell</i> , 2020, 182, 1252-1270.e34.	28.9	259
54	Coping resources of heart failure patients – a comparison with cancer patients and individuals having no chronic condition results from the esther study. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2020, 49, 829-835.	1.6	3

#	ARTICLE	IF	CITATIONS
55	Development and Validation of an LC-MS-Based Quantification Assay for New Therapeutic Antibodies: Application to a Novel Therapy against Herpes Simplex Virus. <i>ACS Omega</i> , 2020, 5, 24329-24339.	3.5	10
56	Interaction of Hydroxychloroquine with Pharmacokinetically Important Drug Transporters. <i>Pharmaceutics</i> , 2020, 12, 919.	4.5	8
57	Rapid and Sensitive Quantification of Osimertinib in Human Plasma Using a Fully Validated MALDI-IMS/MS Assay. <i>Cancers</i> , 2020, 12, 1897.	3.7	14
58	Using the Causal Inference Framework to Support Individualized Drug Treatment Decisions Based on Observational Healthcare Data. <i>Clinical Epidemiology</i> , 2020, Volume 12, 1223-1234.	3.0	5
59	New Insights Into the Pharmacokinetics of Vancomycin After Oral and Intravenous Administration: An Investigation in Beagle Dogs. <i>Journal of Pharmaceutical Sciences</i> , 2020, 109, 2090-2094.	3.3	6
60	Pain severity and analgesics use in the community-dwelling older population: a drug utilization study from Germany. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 1695-1707.	1.9	3
61	An Underestimated Factor: The Extent of Cross-Reactions Modifying APIs in Surface-Modified Liposomal Preparations Caused by Comprised Activated Lipids. <i>Molecules</i> , 2020, 25, 4436.	3.8	2
62	Medication beliefs and use of medication lists – is there a connection? Results from a before-and-after study in Germany. <i>BMC Geriatrics</i> , 2020, 20, 116.	2.7	2
63	A framework to build similarity-based cohorts for personalized treatment advice – a standardized, but flexible workflow with the R package SimBaCo. <i>PLoS ONE</i> , 2020, 15, e0233686.	2.5	5
64	Nobiletin, sinensetin, and tangeretin are the main perpetrators in clementines provoking food-drug interactions in vitro. <i>Food Chemistry</i> , 2020, 319, 126578.	8.2	21
65	Ultra-sensitive bioanalysis of the therapeutic peptide exenatide for accurate pharmacokinetic analyses at effective plasma concentrations utilizing UPLC-MS/MS. <i>Journal of Pharmaceutical Analysis</i> , 2020, 10, 233-239.	5.3	5
66	Drug-Drug Interactions with Direct Oral Anticoagulants. <i>Clinical Pharmacokinetics</i> , 2020, 59, 967-980.	3.5	76
67	Application of a microdosed cocktail of 3 oral factor Xa inhibitors to study drug-drug interactions with different perpetrator drugs. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1632-1641.	2.4	14
68	Methods to Assess Patient Preferences in Old Age Pharmacotherapy – A Systematic Review. <i>Patient Preference and Adherence</i> , 2020, Volume 14, 467-497.	1.8	9
69	Impact of pantoprazole on absorption and disposition of hydroxychloroquine, a drug used in Corona Virus Disease-19 (Covid-19): A structured summary of a study protocol for a randomised controlled trial. <i>Trials</i> , 2020, 21, 584.	1.6	3
70	Development of an algorithm to detect and reduce complexity of drug treatment and its technical realisation. <i>BMC Medical Informatics and Decision Making</i> , 2020, 20, 154.	3.0	7
71	Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial. <i>Npj Vaccines</i> , 2020, 5, 10.	6.0	34
72	Reporter cell assay-based functional quantification of TNF- $\alpha$ -antagonists in serum – a proof-of-principle study for adalimumab. <i>Analytical Biochemistry</i> , 2020, 596, 113646.	2.4	3

#	ARTICLE	IF	CITATIONS
73	Advances in Clinical Pharmacology: Rapid Detection of Small Molecules in Solid Samples at Atmospheric Pressure Using Desorption Electrospray Ionization. <i>OMICS A Journal of Integrative Biology</i> , 2020, 24, 53-54.	2.0	4
74	Rapid and Sensitive Drug Quantification in Tissue Sections Using Matrix Assisted Laser Desorption Ionization-Ion Mobility-Mass Spectrometry Profiling. <i>Journal of the American Society for Mass Spectrometry</i> , 2020, 31, 742-751.	2.8	13
75	Ambrisentan use in a HIV-1 infected patient with end-stage renal disease and pulmonary hypertension: minimal removal by hemodialysis - a case report. <i>BMC Nephrology</i> , 2020, 21, 24.	1.8	3
76	Individual factors increasing complexity of drug treatmentâ€”a narrative review. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 745-754.	1.9	13
77	Post-extraction disulfide bond cleavage for MS/MS quantification of collision-induced dissociation-resistant cystine-cyclized peptides and its application to the ultra-sensitive UPLC-MS/MS bioanalysis of octreotide in plasma. <i>Analytica Chimica Acta</i> , 2020, 1114, 42-49.	5.4	5
78	Ultra-sensitive quantification of the therapeutic cyclic peptide bremelanotide utilizing UHPLC-MS/MS for evaluation of its oral plasma pharmacokinetics. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 186, 113276.	2.8	2
79	Are Anticholinergic Symptoms a Risk Factor for Falls in Older General Practice Patients With Polypharmacy? Study Protocol for the Development and Validation of a Prognostic Model. <i>Frontiers in Pharmacology</i> , 2020, 11, 577747.	3.5	4
80	The Experimental TASK-1 Potassium Channel Inhibitor A293 Can Be Employed for Rhythm Control of Persistent Atrial Fibrillation in a Translational Large Animal Model. <i>Frontiers in Physiology</i> , 2020, 11, 629421.	2.8	16
81	An Electronic Medication Module to Improve Health Literacy in Patients With Type 2 Diabetes Mellitus: Pilot Randomized Controlled Trial. <i>JMIR Formative Research</i> , 2020, 4, e13746.	1.4	9
82	AgeWell.de â€” study protocol of a pragmatic multi-center cluster-randomized controlled prevention trial against cognitive decline in older primary care patients. <i>BMC Geriatrics</i> , 2019, 19, 203.	2.7	34
83	An ultra-sensitive UHPLC-MS/MS assay for the quantification of orally administered vancomycin in plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 174, 633-638.	2.8	8
84	An ultrasensitive UPLCâ€”MS/MS assay for the quantification of the therapeutic peptide liraglutide in plasma to assess the oral and nasal bioavailability in beagle dogs. <i>Bioanalysis</i> , 2019, 11, 887-898.	1.5	9
85	Longitudinal association between panic disorder and health care costs in older adults. <i>Depression and Anxiety</i> , 2019, 36, 1135-1142.	4.1	1
86	Unexpected excessive apixaban exposure: case report of a patient with polymorphisms of multiple apixaban elimination pathways. <i>BMC Pharmacology &amp; Toxicology</i> , 2019, 20, 53.	2.4	15
87	Simultaneous phenotyping of CYP2E1 and CYP3A using oral chlorzoxazone and midazolam microdoses. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2310-2320.	2.4	17
88	Prolongedâ€”Release Tacrolimus Is Less Susceptible to Interaction With the Strong <sc>CYP</sc>3A Inhibitor Voriconazole in Healthy Volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 1290-1298.	4.7	19
89	Microdosed midazolam for the determination of cytochrome P450 3A activity: Development and clinical evaluation of a buccal film. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 135, 77-82.	4.0	3
90	Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drugâ€”Drug Interactions with Potential Perpetrator Drugs. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1155-1163.	3.5	12

#	ARTICLE	IF	CITATIONS
91	Perpetrator effects of ciclosporin (Pâ€glycoprotein inhibitor) and its combination with fluconazole (CYP3A inhibitor) on the pharmacokinetics of rivaroxaban in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1528-1537.	2.4	21
92	The Role of Adherence Thresholds for Development and Performance Aspects of a Prediction Model for Direct Oral Anticoagulation Adherence. <i>Frontiers in Pharmacology</i> , 2019, 10, 113.	3.5	8
93	Improving eye-drop administration skills of patients â€ A multicenter parallel-group cluster-randomized controlled trial. <i>PLoS ONE</i> , 2019, 14, e0212007.	2.5	6
94	A follow-up report on potential drug interactions with clemintines: Two single case experiments show no effect on CYP3A-dependent midazolam clearance. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 133, 54-58.	4.0	2
95	Changing the medication documentation process for discharge: impact on clinical routine and documentation qualityâ€a process analysis. <i>European Journal of Hospital Pharmacy</i> , 2019, 29, ejhpharm-2019-002027.	1.1	0
96	Plasma Drug Concentrations in Children Receiving Pulmonary Arterial Hypertension Combination Treatment. <i>Respiration</i> , 2019, 97, 92-92.	2.6	1
97	Association of generalized anxiety symptoms and panic with health care costs in older ageâ€Results from the ESTHER cohort study. <i>Journal of Affective Disorders</i> , 2019, 245, 978-986.	4.1	9
98	A novel superior medication-based chronic disease score predicted all-cause mortality in independent geriatric cohorts. <i>Journal of Clinical Epidemiology</i> , 2019, 105, 112-124.	5.0	14
99	Evidence for underuse and overuse of antidepressants in older adults: Results of a large populationâ€based study. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 539-547.	2.7	28
100	A Proposal for the Retrospective Identification and Categorization of Older People With Functional Impairments in Scientific Studiesâ€Recommendations of the Medication and Quality of Life in Frail Older Persons (MedQoL) Research Group. <i>Journal of the American Medical Directors Association</i> , 2019, 20, 138-146.	2.5	25
101	Use of medication lists: A population-based approach to increase the prevalence of medication lists within a region in Germany. Â€pre-post study. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2019, 57, 375-383.	0.6	2
102	Decreasing Use of Chemotherapy in Older Patients With Stage III Colon Cancer Irrespective of Comorbidities. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1089-1099.	4.9	28
103	Structure and Content of Drug Monitoring Advices Included in Discharge Letters at Interfaces of Care: Exploratory Analysis Preceding Database Development. <i>JMIR Medical Informatics</i> , 2019, 7, e10832.	2.6	0
104	Drugâ€Drug Interaction Potential of the HBV and HDV Entry Inhibitor Myrcludex B Assessed <i>in vitro</i>. <i>Antiviral Therapy</i> , 2018, 23, 267-275.	1.0	12
105	Systematic identification of suspected anthelmintic benzimidazole metabolites using LCâ€MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 151, 151-158.	2.8	9
106	Reply to Truffot et al. <i>Clinical Infectious Diseases</i> , 2018, 66, 1644-1646.	5.8	0
107	No, we are notâ€we keep forgetting the right ventricle. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 141-143.	1.9	2
108	High Accumulation of Metformin in Colonic Tissue of Subjects With Diabetes or the Metabolic Syndrome. <i>Gastroenterology</i> , 2018, 154, 1543-1545.	1.3	27

#	ARTICLE	IF	CITATIONS
109	A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer. <i>Oncolimmunology</i> , 2018, 7, e1303584.	4.6	41
110	Frailty and healthcare costs—longitudinal results of a prospective cohort study. <i>Age and Ageing</i> , 2018, 47, 233-241.	1.6	145
111	Simultaneous quantification of direct oral anticoagulants currently used in anticoagulation therapy. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 148, 238-244.	2.8	37
112	Patient Experiences With Handling of Analgesic Transdermal Patches and Challenges in Correct Drug Administration: A Pilot Study on Patient Education. <i>Journal of Patient Safety</i> , 2018, 14, e97-e101.	1.7	2
113	How to meet patients&#39; individual needs for drug information - a scoping review. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 2339-2355.	1.8	46
114	Clinical trial protocol of the ASTER trial: a double-blind, randomized, placebo-controlled phase III trial evaluating the use of acetylsalicylic acid (ASA) for enhanced early detection of colorectal neoplasms. <i>BMC Cancer</i> , 2018, 18, 914.	2.6	5
115	Rivaroxaban and macitentan can be coadministered without dose adjustment but the combination of rivaroxaban and St John's wort should be avoided. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2903-2913.	2.4	17
116	The associations of geriatric syndromes and other patient characteristics with the current and future use of potentially inappropriate medications in a large cohort study. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 1633-1644.	1.9	47
117	Effectiveness of a complex intervention on Prioritising Multimедication in Multimorbidity (PRIMUM) in primary care: results of a pragmatic cluster randomised controlled trial. <i>BMJ Open</i> , 2018, 8, e017740.	1.9	63
118	Prediction of Drug-Related Risks Using Clinical Context Information in Longitudinal Claims Data. <i>Value in Health</i> , 2018, 21, 1390-1398.	0.3	8
119	The impact of potentially inappropriate medication on the development of health care costs and its moderation by the number of prescribed substances. Results of a retrospective matched cohort study. <i>PLoS ONE</i> , 2018, 13, e0198004.	2.5	20
120	Dried-Blood-Spot Technique to Monitor Direct Oral Anticoagulants: Clinical Validation of a UPLC-MS/MS-Based Assay. <i>Analytical Chemistry</i> , 2018, 90, 9395-9402.	6.5	33
121	Identification, Biosynthesis, and Decapping of NAD-Capped RNAs in <i>B. Subtilis</i> . <i>Cell Reports</i> , 2018, 24, 1890-1901.e8.	6.4	61
122	Pill-count and the arithmetic of risk: Evidence that polypharmacy is a health status marker rather than a predictive surrogate for the risk of adverse drug events. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2018, 56, 572-576.	0.6	8
123	What do laypeople consider "medication"™ and are they aware of modulators of a drug's™ effects?. <i>European Journal of Hospital Pharmacy</i> , 2018, 25, 218-221.	1.1	0
124	The Interaction between Sildenafil and Phenobarbital in Infants with Congenital Heart Defects. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO2-15-19.	0.0	0
125	Prolyl Hydroxylase Inhibition Enhances Liver Regeneration Without Induction of Tumor Growth. <i>Annals of Surgery</i> , 2017, 265, 782-791.	4.2	31
126	A Longitudinal Investigation of Willingness to Pay for Health Insurance in Germany. <i>Health Services Research</i> , 2017, 52, 1099-1117.	2.0	9



#	ARTICLE	IF	CITATIONS
127	How can we define and analyse drug exposure more precisely to improve the prediction of hospitalizations in longitudinal (claims) data?. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 373-380.	1.9	5
128	Health Service Use, Costs, and Adverse Events Associated with Potentially Inappropriate Medication in Old Age in Germany: Retrospective Matched Cohort Study. <i>Drugs and Aging</i> , 2017, 34, 289-301.	2.7	48
129	Semisimultaneous Midazolam Administration to Evaluate the Time Course of CYP3A Activation by a Single Oral Dose of Efavirenz. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 899-905.	2.0	11
130	Definition of variables required for comprehensive description of drug dosage and clinical pharmacokinetics. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 633-641.	1.9	1
131	Comparison of Nine Instruments to Calculate Anticholinergic Load in a Large Cohort of Older Outpatients: Association with Cognitive and Functional Decline, Falls, and Use of Laxatives. <i>American Journal of Geriatric Psychiatry</i> , 2017, 25, 531-540.	1.2	30
132	Target-Mediated Drug Disposition Pharmacokinetic-Pharmacodynamic Model of Bosentan and Endothelin-1. <i>Clinical Pharmacokinetics</i> , 2017, 56, 1499-1511.	3.5	10
133	Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment. <i>Respiration</i> , 2017, 94, 26-37.	2.6	19
134	Substantial Impairment of Voriconazole Clearance by High-Dose Meropenem in a Patient With Renal Failure. <i>Clinical Infectious Diseases</i> , 2017, 65, 1033-1036.	5.8	11
135	Risk factors of adverse health outcomes after hospital discharge modifiable by clinical pharmacist interventions: a review with a systematic approach. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2163-2178.	2.4	12
136	Ultra-sensitive and selective quantification of endothelin-1 in human plasma using ultra-performance liquid chromatography coupled to tandem mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 142, 84-90.	2.8	6
137	Autoinhibitory properties of the parent but not of the N-oxide metabolite contribute to infusion rate-dependent voriconazole pharmacokinetics. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1954-1965.	2.4	19
138	Investigating the Additive Interaction of QT-Prolonging Drugs in Older People Using Claims Data. <i>Drug Safety</i> , 2017, 40, 133-144.	3.2	29
139	Clementine juice has the potential for drug interactions – In vitro comparison with grapefruit and mandarin juice. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 97, 247-256.	4.0	38
140	Intracellular vorinostat accumulation and its relationship to histone deacetylase activity in soft tissue sarcoma patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 433-439.	2.3	7
141	Tadalafil has biologic activity in human melanoma. Results of a pilot trial with tadalafil in patients with metastatic Melanoma (TaMe). <i>OncImmunology</i> , 2017, 6, e1326440.	4.6	74
142	Simultaneous quantification of endothelin receptor antagonists and phosphodiesterase 5 inhibitors currently used in pulmonary arterial hypertension. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 143, 291-298.	2.8	14
143	Interprofessional communication between community pharmacists and general practitioners: a qualitative study. <i>International Journal of Clinical Pharmacy</i> , 2017, 39, 495-506.	2.1	35
144	Is Polypharmacy Associated with Frailty in Older People? Results From the ESTHER Cohort Study. <i>Journal of the American Geriatrics Society</i> , 2017, 65, e27-e32.	2.6	154

#	ARTICLE	IF	CITATIONS
145	Cyclic guanosine monophosphate modulates accumulation of phosphodiesterase 5 inhibitors in human platelets. <i>Biochemical Pharmacology</i> , 2017, 145, 54-63.	4.4	10
146	A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat for pediatric and adult patients and its application for dose specification. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 1013-1026.	2.3	20
147	Association of preventable adverse drug events with inpatients' length of stay-A propensity-matched cohort study. <i>International Journal of Clinical Practice</i> , 2017, 71, e12990.	1.7	19
148	Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature. <i>Therapeutic Advances in Psychopharmacology</i> , 2017, 7, 251-264.	2.7	43
149	Refining estimates of prescription durations by using observed covariates in pharmacoepidemiologic databases: Necessary refinements to stimulate alternative approaches. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 1135-1137.	1.9	2
150	Real-world complexity of atrial fibrillation treatment with oral anticoagulants: design and interpretation of pharmacoepidemiological studies. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2321-2324.	2.4	1
151	Oral delivery of vancomycin by tetraether lipid liposomes. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 108, 111-118.	4.0	69
152	Pre- and post-diagnostic $\beta$ -blocker use and lung cancer survival: A population-based cohort study. <i>Scientific Reports</i> , 2017, 7, 2911.	3.3	30
153	Medication review in German community pharmacies – Post-hoc analysis of documented drug-related problems and subsequent interventions in the ATHINA-project. <i>Research in Social and Administrative Pharmacy</i> , 2017, 13, 1127-1134.	3.0	20
154	Clarithromycin, Midazolam, and Digoxin: Application of PBPK Modeling to Gain New Insights into Drug-Drug Interactions and Co-medication Regimens. <i>AAPS Journal</i> , 2017, 19, 298-312.	4.4	28
155	ASAMET: A randomized, 2x2 biomarker prevention trial of low-dose aspirin and metformin in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS1591-TPS1591.	1.6	2
156	High accumulation of metformin in colonic tissue of subjects with diabetes or metabolic syndrome.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1557-1557.	1.6	0
157	Venetoclax (ABT-199) Might Act as a Perpetrator in Pharmacokinetic Drug-Drug Interactions. <i>Pharmaceutics</i> , 2016, 8, 5.	4.5	20
158	Dose-Dependent Bioavailability and CYP3A Inhibition Contribute to Non-Linear Pharmacokinetics of Voriconazole. <i>Clinical Pharmacokinetics</i> , 2016, 55, 1535-1545.	3.5	51
159	Pilot study to test the feasibility of a trial design and complex intervention on prioritising medication in multimorbidity in general practices (PRIMUM pilot). <i>BMJ Open</i> , 2016, 6, e011613.	1.9	30
160	Comparative evaluation of methods approximating drug prescription durations in claims data: modeling, simulation, and application to real data. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 1434-1442.	1.9	14
161	First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B. <i>Journal of Hepatology</i> , 2016, 65, 483-489.	3.7	187
162	Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study. <i>Journal of Hepatology</i> , 2016, 65, 490-498.	3.7	321

#	ARTICLE	IF	CITATIONS
163	Treatment with rilpivirine does not alter plasma concentrations of the CYP3A substrates tadalafil and midazolam in humans. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2241-2247.	3.0	5
164	Limitations of the Anticholinergic Activity Assay and Assay-Based Anticholinergic Drug Scales. <i>American Journal of Geriatric Psychiatry</i> , 2016, 24, 1182-1188.	1.2	12
165	Quality of antenatal and childbirth care in rural health facilities in Burkina Faso, Ghana and Tanzania: an intervention study. <i>Tropical Medicine and International Health</i> , 2016, 21, 70-83.	2.3	22
166	Guidance on how to achieve comprehensible patient information leaflets in four steps. <i>International Journal for Quality in Health Care</i> , 2016, 28, 634-638.	1.8	9
167	Age-Dependent Impact of Medication Underuse and Strategies for Improvement. <i>Gerontology</i> , 2016, 62, 491-499.	2.8	6
168	Best practice strategies to safeguard drug prescribing and drug administration: an anthology of expert views and opinions. <i>International Journal of Clinical Pharmacy</i> , 2016, 38, 362-373.	2.1	8
169	Ultrasensitive quantification of the CYP2E1 probe chlorzoxazone and its main metabolite 6-hydroxychlorzoxazone in human plasma using ultra performance liquid chromatography coupled to tandem mass spectrometry after chlorzoxazone microdosing. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1027, 207-213.	2.3	15
170	Associations of frailty with health care costs – results of the ESTHER cohort study. <i>BMC Health Services Research</i> , 2016, 16, 128.	2.2	181
171	Longitudinal evaluation of medication underuse in older outpatients and its association with quality of life. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 877-885.	1.9	19
172	Willingness to pay for health insurance among the elderly population in Germany. <i>European Journal of Health Economics</i> , 2016, 17, 149-158.	2.8	14
173	St. John's wort treatment in women bears risks beyond pharmacokinetic drug interactions. <i>Archives of Toxicology</i> , 2016, 90, 1013-1015.	4.2	4
174	CYP3A activity: towards dose adaptation to the individual. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 479-497.	3.3	49
175	A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGF-receptor 2, in patients with advanced pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3091-3091.	1.6	2
176	The Effect of Induction of CYP3A4 by St John's Wort on Ambrisentan Plasma Pharmacokinetics in Volunteers of known CYP2C19 Genotype. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2015, 116, 423-428.	2.5	19
177	Impact of an electronic clinical decision support system on workflow in antenatal care: the QUALMAT eCDSS in rural health care facilities in Ghana and Tanzania. <i>Global Health Action</i> , 2015, 8, 25756.	1.9	40
178	Loneliness in the elderly is associated with the use of psychotropic drugs. <i>International Journal of Geriatric Psychiatry</i> , 2015, 30, 957-964.	2.7	24
179	Pharmacokinetic interaction of intravenous fentanyl with ketoconazole. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 708-717.	2.0	43
180	Knowledge and training needs of nurses and physicians on unsuitable drugs for patients with dysphagia or feeding tubes. <i>Journal of Clinical Nursing</i> , 2015, 24, 3016-3019.	3.0	9

#	ARTICLE	IF	CITATIONS
181	The impact of pharmaceutical care interventions for medication underuse in older people: a systematic review and meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 768-776.	2.4	38
182	Medication Underuse in Aging Outpatients with Cardiovascular Disease: Prevalence, Determinants, and Outcomes in a Prospective Cohort Study. <i>PLoS ONE</i> , 2015, 10, e0136339.	2.5	31
183	A prospective three-step intervention study to prevent medication errors in drug handling in paediatric care. <i>Journal of Clinical Nursing</i> , 2015, 24, 101-114.	3.0	28
184	Effects of adrenergic mitotane on drug elimination pathways assessed in vitro. <i>Endocrine</i> , 2015, 49, 842-853.	2.3	23
185	Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 278-285.	2.4	59
186	Desmethyl bosentan displays a similar in vitro interaction profile as bosentan. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015, 30, 80-86.	2.6	4
187	Cellular uptake kinetics of bortezomib in relation to efficacy in myeloma cells and the influence of drug transporters. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 281-291.	2.3	22
188	Promising adoption of an electronic clinical decision support system for antenatal and intrapartum care in rural primary healthcare facilities in sub-Saharan Africa: The QUALMAT experience. <i>International Journal of Medical Informatics</i> , 2015, 84, 647-657.	3.3	47
189	Quantitative bile acid profiling by liquid chromatography quadrupole time-of-flight mass spectrometry: monitoring hepatitis B therapy by a novel Na <sup>+</sup> -taurocholate cotransporting polypeptide inhibitor. <i>Analytical and Bioanalytical Chemistry</i> , 2015, 407, 6815-6825.	3.7	35
190	Role of NR1I2 (pregnane X receptor) polymorphisms in head and neck squamous cell carcinoma. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2015, 388, 1141-1150.	3.0	12
191	Tailoring of alerts substantially reduces the alert burden in computerized clinical decision support for drugs that should be avoided in patients with renal disease. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2015, 22, 881-887.	4.4	18
192	Comment on: Pharmacokinetics of the co-administration of boceprevir and St John's wort to male and female healthy volunteers. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 322-323.	3.0	0
193	Use of Microdose Phenotyping to Individualise Dosing of Patients. <i>Clinical Pharmacokinetics</i> , 2015, 54, 893-900.	3.5	16
194	Health service use and costs associated with excess weight in older adults in Germany. <i>Age and Ageing</i> , 2015, 44, 616-623.	1.6	22
195	Development and evaluation of an algorithm to facilitate drug prescription for inpatients with feeding tubes. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 489-497.	1.9	1
196	Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial. <i>OncImmunology</i> , 2015, 4, e1001217.	4.6	41
197	Characteristics of medication schedules used by elderly ambulatory patients. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1109-1120.	1.9	9
198	Different methods, different results—how do available methods link a patient's anticholinergic load with adverse outcomes?. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1299-1314.	1.9	47

#	ARTICLE	IF	CITATIONS
199	Swallowing Tablets and Capsules Increases the Risk of Penetration and Aspiration in Patients with Stroke-Induced Dysphagia. <i>Dysphagia</i> , 2015, 30, 571-582.	1.8	42
200	Dried Blood Spot Technique for the Monitoring of Ambrisentan, Bosentan, Sildenafil, and Tadalafil in Patients with Pulmonary Arterial Hypertension. <i>Analytical Chemistry</i> , 2015, 87, 12112-12120.	6.5	20
201	Interaction Potential of the Multitargeted Receptor Tyrosine Kinase Inhibitor Dovitinib with Drug Transporters and Drug Metabolising Enzymes Assessed in Vitro. <i>Pharmaceutics</i> , 2014, 6, 632-650.	4.5	18
202	CYP3A activity in severe liver cirrhosis correlates with C <sub>h</sub> and model for end-stage liver disease (MELD) scores. <i>British Journal of Clinical Pharmacology</i> , 2014, 77, 160-169.	2.4	53
203	Clarithromycin substantially increases steady-state bosentan exposure in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 2014, 77, 141-148.	2.4	17
204	Two Techniques to Make Swallowing Pills Easier. <i>Annals of Family Medicine</i> , 2014, 12, 550-552.	1.9	36
205	An N-of-1 Trial as an Individualized Withdrawal Treatment Approach to Psychological Methylphenidate Dependence. <i>Psychotherapy and Psychosomatics</i> , 2014, 83, 379-381.	8.8	1
206	Pilot study to assess the influence of an enhanced medication plan on patient knowledge at hospital discharge. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 1243-1250.	1.9	22
207	Quantification of vorinostat and its main metabolites in plasma and intracellular vorinostat in PBMCs by liquid chromatography coupled to tandem mass spectrometry and its relation to histone deacetylase activity in human blood. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014, 964, 212-221.	2.3	14
208	Inequalities in out-of-pocket payments for health care services among elderly Germans – results of a population-based cross-sectional study. <i>International Journal for Equity in Health</i> , 2014, 13, 3.	3.5	32
209	Health care costs in the elderly in Germany: an analysis applying Andersen's behavioral model of health care utilization. <i>BMC Health Services Research</i> , 2014, 14, 71.	2.2	65
210	Inappropriate crushing information on ward lists: cytotoxic drugs, capsules, and modified release formulations are gravely neglected. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 565-573.	1.9	8
211	Stability of the proteasome inhibitor bortezomib in cell based assays determined by ultra-high performance liquid chromatography coupled to tandem mass spectrometry. <i>Journal of Chromatography A</i> , 2014, 1345, 128-138.	3.7	9
212	Drug interactions with phytotherapeutics in oncology. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 359-377.	3.3	55
213	Indirect evidence for proton pump inhibitor failure in patients taking them independent of meals. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 768-772.	1.9	6
214	Do you have any questions about your medication?. <i>Patient Education and Counseling</i> , 2014, 97, 434.	2.2	9
215	A systematic review of medication administration errors with transdermal patches. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 1101-1114.	2.4	17
216	Substantially increased sildenafil bioavailability after sublingual administration in children with congenital heart disease: two case reports. <i>Journal of Medical Case Reports</i> , 2014, 8, 171.	0.8	10

#	ARTICLE	IF	CITATIONS
217	Telaprevir is a substrate and moderate inhibitor of P-glycoprotein, a strong inducer of ABCG2, but not an activator of PXR in vitro. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 184-188.	2.5	16
218	What, if all alerts were specific – Estimating the potential impact on drug interaction alert burden. <i>International Journal of Medical Informatics</i> , 2014, 83, 285-291.	3.3	75
219	Pharmacokinetic interaction profile of riociguat, a new soluble guanylate cyclase stimulator, in vitro. <i>Pulmonary Pharmacology and Therapeutics</i> , 2014, 28, 130-137.	2.6	17
220	Nesting doctoral students in collaborative North-South partnerships for health systems research. <i>Global Health Action</i> , 2014, 7, 24070.	1.9	16
221	Health workers' knowledge of and attitudes towards computer applications in rural African health facilities. <i>Global Health Action</i> , 2014, 7, 24534.	1.9	67
222	Influence of St. John's wort on the steady-state pharmacokinetics and metabolism of bosentan. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2014, 52, 328-336.	0.6	13
223	Lack of a clinically significant interaction of grapefruit juice with ambrisentan and bosentan in healthy adults. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2014, 52, 957-964.	0.6	4
224	Interaction of ambrisentan with clarithromycin and its modulation by polymorphic SLCO1B1. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 1785-1793.	1.9	25
225	Reduced exposure variability of the CYP3A substrate simvastatin by dose individualization to CYP3A activity. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 1199-1204.	2.0	9
226	Quality of prenatal and maternal care: bridging the know-do gap (QUALMAT study): an electronic clinical decision support system for rural Sub-Saharan Africa. <i>BMC Medical Informatics and Decision Making</i> , 2013, 13, 44.	3.0	69
227	On the alert: future priorities for alerts in clinical decision support for computerized physician order entry identified from a European workshop. <i>BMC Medical Informatics and Decision Making</i> , 2013, 13, 111.	3.0	81
228	In-vitro evaluation of chronic alcohol effects on expression of drug-metabolizing and drug-transporting proteins. <i>Journal of Pharmacy and Pharmacology</i> , 2013, 65, 1518-1525.	2.4	13
229	Opportunities to Reduce Medication Regimen Complexity. <i>Drug Safety</i> , 2013, 36, 31-41.	3.2	41
230	Influence of sildenafil and tadalafil on the enzyme- and transporter-inducing effects of bosentan and ambrisentan in LS180 cells. <i>Biochemical Pharmacology</i> , 2013, 85, 265-273.	4.4	50
231	Association of Liver Stiffness with Hepatic Expression of Pharmacokinetically Important Genes in Alcoholic Liver Disease. <i>Alcoholism: Clinical and Experimental Research</i> , 2013, 37, E17-22.	2.4	17
232	Minor role of pregnane-x-receptor for acquired multidrug resistance in head and neck squamous cell carcinoma in vitro. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1335-1343.	2.3	16
233	Difficulties swallowing solid oral dosage forms in a general practice population: prevalence, causes, and relationship to dosage forms. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 937-948.	1.9	186
234	Potential of the novel antiretroviral drug rilpivirine to modulate the expression and function of drug transporters and drug-metabolising enzymes in vitro. <i>International Journal of Antimicrobial Agents</i> , 2013, 41, 484-487.	2.5	45

#	ARTICLE	IF	CITATIONS
235	Interaction profile of macitentan, a new non-selective endothelin-1 receptor antagonist, in vitro. <i>European Journal of Pharmacology</i> , 2013, 701, 168-175.	3.5	41
236	Liposomal Sphingomyelin Influences the Cellular Lipid Profile of Human Lymphoblastic Leukemia Cells without Effect on P-Glycoprotein Activity. <i>Molecular Pharmaceutics</i> , 2013, 10, 1020-1034.	4.6	6
237	Effect of the CYP3A inhibitor ketoconazole on the PXR-mediated induction of CYP3A activity. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 507-513.	1.9	31
238	Development of a standardized knowledge base to generate individualized medication plans automatically with drug administration recommendations. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 37-46.	2.4	6
239	Trimethoprimâ€“metformin interaction and its genetic modulation by <sc>OCT</sc>2 and <sc>MATE1</sc> transporters. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 787-796.	2.4	67
240	Fentanyl Pharmacokinetics is not Dependent on Hepatic Uptake by Organic Anionâ€“Transporting Polypeptide 1B1 in Human Beings. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2013, 113, 43-48.	2.5	9
241	Safeguarding the process of drug administration with an emphasis on electronic support tools. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 25-36.	2.4	14
242	Do we prescribe what patients prefer? Pilot study to assess patient preferences for medication regimen characteristics. <i>Patient Preference and Adherence</i> , 2012, 6, 679.	1.8	30
243	Cellular Pharmacokinetic/Pharmacodynamic Relationship of Platinum Cytostatics in Head and Neck Squamous Cell Carcinoma Evaluated by Liquid Chromatography Coupled to Tandem Mass Spectrometry. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012, 341, 51-58.	2.5	11
244	Drug Interaction of Efavirenz and Midazolam: Efavirenz Activates the CYP3A-Mediated Midazolam 1â€“Hydroxylation In Vitro. <i>Drug Metabolism and Disposition</i> , 2012, 40, 1178-1182.	3.3	27
245	Rifampicin alters the expression of reference genes used to normalize real-time quantitative RT-PCR data. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2012, 385, 1025-1034.	3.0	8
246	7-Aminoactinomycin D for apoptosis staining in flow cytometry. <i>Analytical Biochemistry</i> , 2012, 429, 79-81.	2.4	91
247	Quantification of retinoid concentrations in human serum and brain tumor tissues. <i>Analytica Chimica Acta</i> , 2012, 725, 57-66.	5.4	11
248	How to improve drug dosing for patients with renal impairment in primary care - a cluster-randomized controlled trial. <i>BMC Family Practice</i> , 2012, 13, 91.	2.9	45
249	Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer. <i>BMC Cancer</i> , 2012, 12, 361.	2.6	43
250	Development and evaluation of a computerised clinical decision support system for switching drugs at the interface between primary and tertiary care. <i>BMC Medical Informatics and Decision Making</i> , 2012, 12, 137.	3.0	15
251	Can a feedback report and training session on medication counseling for general practitioners improve patient satisfaction with information on medicines?. <i>Patient Preference and Adherence</i> , 2012, 6, 179.	1.8	9
252	Objective assessment of nonadherence and unknown co-medication in hospitalized patients. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 1191-1199.	1.9	9

#	ARTICLE	IF	CITATIONS
253	eâ€œSPC â€œ delivering drug information in the 21st century: developing new approaches to deliver drug information to prescribers. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 12-15.	2.4	19
254	Patients' Beliefs about Medicines in a primary care setting in Germany. <i>Journal of Evaluation in Clinical Practice</i> , 2012, 18, 409-413.	1.8	78
255	Quantification of femtomolar concentrations of the CYP3A substrate midazolam and its main metabolite 1â€²-hydroxymidazolam in human plasma using ultra performance liquid chromatography coupled to tandem mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2012, 402, 2439-2450.	3.7	59
256	Assessment of a computerised decision support system for allergic rhino-conjunctivitis counselling in German pharmacy. <i>International Journal of Clinical Pharmacy</i> , 2012, 34, 17-22.	2.1	17
257	Pharmacokinetics of 5-Aminofluorescein-Albumin, a Novel Fluorescence Marker of Brain Tumors During Surgery. <i>Journal of Clinical Pharmacology</i> , 2011, 51, 672-678.	2.0	15
258	Treatment of pulmonary arterial hypertension (PAH): Updated Recommendations of the Cologne Consensus Conference 2011. <i>International Journal of Cardiology</i> , 2011, 154, S20-S33.	1.7	46
259	Modulators of Very Low Voriconazole Concentrations in Routine Therapeutic Drug Monitoring. <i>Therapeutic Drug Monitoring</i> , 2011, 33, 86-93.	2.0	60
260	Drug utilization patterns and reported health status in ethnic German migrants (Aussiedler) in Germany: a cross-sectional study. <i>BMC Public Health</i> , 2011, 11, 509.	2.9	14
261	Differential modulation of the expression of important drug metabolising enzymes and transporters by endothelin-1 receptor antagonists ambrisentan and bosentan in vitro. <i>European Journal of Pharmacology</i> , 2011, 660, 298-304.	3.5	33
262	Interaction potential of the endothelin-A receptor antagonist atrasentan with drug transporters and drug-metabolising enzymes assessed in vitro. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 1093-1098.	2.3	8
263	Knockdown of caveolin-1 decreases activity of breast cancer resistance protein (BCRP/ABCG2) and increases chemotherapeutic sensitivity. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2011, 383, 1-11.	3.0	18
264	Frequency of the SLCO1B1 388A&gt;G and the 521T&gt;C polymorphism in Tanzania genotyped by a new LightCyclerÂ®-based method. <i>European Journal of Clinical Pharmacology</i> , 2011, 67, 1139-1145.	1.9	32
265	Evaluation of drug transporters' significance for multidrug resistance in head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2011, 33, 959-968.	2.0	24
266	Daily Honey Consumption Does Not Change CYP3A Activity in Humans. <i>Journal of Clinical Pharmacology</i> , 2011, 51, 1223-1232.	2.0	6
267	Potential of novel antiretrovirals to modulate expression and function of drug transporters in vitro. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 802-812.	3.0	60
268	Factors influencing alert acceptance: a novel approach for predicting the success of clinical decision support. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2011, 18, 479-484.	4.4	107
269	Sildenafil Preserves Lung Endothelial Function and Prevents Pulmonary Vascular Remodeling in a Rat Model of Diastolic Heart Failure. <i>Circulation: Heart Failure</i> , 2011, 4, 198-206.	3.9	69
270	Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2350-2361.	3.0	54



#	ARTICLE	IF	CITATIONS
271	Interaction Potential of Etravirine with Drug Transporters Assessed <i>In Vitro</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 1282-1284.	3.2	31
272	Pharmacokinetics of linezolid in septic patients with and without extended dialysis. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 291-298.	1.9	68
273	Prevention of adverse drug reactions in intensive care patients by personal intervention based on an electronic clinical decision support system. <i>Intensive Care Medicine</i> , 2010, 36, 665-672.	8.2	76
274	Appropriateness of timing of drug administration in electronic prescriptions. <i>International Journal of Clinical Pharmacy</i> , 2010, 32, 162-171.	1.4	10
275	A purging procedure for pantoprazole and 4-lumen catheters to prevent IV drug incompatibilities. <i>International Journal of Clinical Pharmacy</i> , 2010, 32, 663-669.	1.4	12
276	Coded entry versus free-text and alert overrides: What you get depends on how you ask. <i>International Journal of Medical Informatics</i> , 2010, 79, 792-796.	3.3	15
277	Misspellings in drug information system queries: Characteristics of drug name spelling errors and strategies for their prevention. <i>International Journal of Medical Informatics</i> , 2010, 79, 832-839.	3.3	18
278	Impact of drug interactions, dosage, and duration of therapy on the risk of hip fracture associated with benzodiazepine use in older adults. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 1248-1255.	1.9	82
279	Assessing reported adherence to pharmacological treatment recommendations. Translation and evaluation of the Medication Adherence Report Scale (MARS) in Germany. <i>Journal of Evaluation in Clinical Practice</i> , 2010, 16, 574-579.	1.8	132
280	No Evidence for Induction of ABC Transporters in Peripheral Blood Mononuclear Cells in Humans after 14 Days of Efavirenz Treatment. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4185-4191.	3.2	30
281	Impact of drug transporters on cellular resistance towards saquinavir and darunavir. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2319-2328.	3.0	75
282	Pharmacokinetics of Sulfobutylether-Beta-Cyclodextrin and Voriconazole in Patients with End-Stage Renal Failure during Treatment with Two Hemodialysis Systems and Hemodiafiltration. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 2596-2602.	3.2	75
283	Impact of ATP-Binding Cassette Transporters on Human Immunodeficiency Virus Therapy. <i>International Review of Cell and Molecular Biology</i> , 2010, 280, 219-279.	3.2	22
284	Variability of Pharmacokinetic Drug-drug Interactions and Its Consequences. <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , 2009, 40, 197S-198S.	0.1	0
285	<i>CYP2C19</i> Genotype Is a Major Factor Contributing to the Highly Variable Pharmacokinetics of Voriconazole. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 196-204.	2.0	174
286	Interaction of Thiazolidinediones (Glitazones) with the ATP-Binding Cassette Transporters P-Glycoprotein and Breast Cancer Resistance Protein. <i>Pharmacology</i> , 2009, 84, 264-270.	2.2	33
287	Efavirenz Treatment and False-Positive Results in Benzodiazepine Screening Tests. <i>Clinical Infectious Diseases</i> , 2009, 48, 1787-1789.	5.8	18
288	Substantial reduction of inappropriate tablet splitting with computerised decision support: a prospective intervention study assessing potential benefit and harm. <i>BMC Medical Informatics and Decision Making</i> , 2009, 9, 30.	3.0	24

#	ARTICLE	IF	CITATIONS
289	Involvement of drug transporters in the synergistic action of FOLFOX combination chemotherapy. <i>Biochemical Pharmacology</i> , 2009, 78, 1366-1373.	4.4	57
290	Drug Dose Adjustments in Patients With Renal Impairment. <i>American Journal of Kidney Diseases</i> , 2009, 54, 983-984.	1.9	7
291	The A14-scale: development and evaluation of a questionnaire for assessment of adherence and individual barriers. <i>International Journal of Clinical Pharmacy</i> , 2009, 31, 426-431.	1.4	25
292	Prescribing errors in patients with documented drug allergies: comparison of ICD-10 coding and written patient notes. <i>International Journal of Clinical Pharmacy</i> , 2009, 31, 464-472.	1.4	21
293	Pro-active provision of drug information as a technique to address overdosing in intensive-care patients with renal insufficiency. <i>European Journal of Clinical Pharmacology</i> , 2009, 65, 823-829.	1.9	18
294	Successful strategy to improve the specificity of electronic statin drug interaction alerts. <i>European Journal of Clinical Pharmacology</i> , 2009, 65, 1149-1157.	1.9	27
295	Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. <i>British Journal of Clinical Pharmacology</i> , 2009, 68, 906-915.	2.4	152
296	Psychometric Properties of a German Version of the "Satisfaction with Information about Medicines Scale" (SIMS-D). <i>Value in Health</i> , 2009, 12, 1176-1179.	0.3	19
297	One-year follow-up on procedure to prevent i.v. drug incompatibilities in an intensive care unit. <i>American Journal of Health-System Pharmacy</i> , 2009, 66, 1250-1253.	1.0	7
298	Multidisciplinary pain management based on a computerized clinical decision support system in cancer pain patients. <i>Pain</i> , 2009, 147, 20-28.	4.2	38
299	Induction of Multiple Drug Transporters by Efavirenz. <i>Journal of Pharmacological Sciences</i> , 2009, 109, 242-250.	2.5	61
300	Prioritising the prevention of medication handling errors. <i>International Journal of Clinical Pharmacy</i> , 2008, 30, 907-915.	1.4	33
301	In vitro metabolism of the opioid tilidine and interaction of tilidine and nortilidine with CYP3A4, CYP2C19, and CYP2D6. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2008, 378, 275-282.	3.0	17
302	Rule-based standardised switching of drugs at the interface between primary and tertiary care. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 319-327.	1.9	11
303	Expression and activity of P-glycoprotein (MDR1/ABCB1) in peripheral blood mononuclear cells from patients with anorexia nervosa compared with healthy controls. <i>International Journal of Eating Disorders</i> , 2008, 41, 432-438.	4.0	5
304	Quantification of cationic anti-malaria agent methylene blue in different human biological matrices using cation exchange chromatography coupled to tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2008, 863, 273-282.	2.3	49
305	Comparison of the induction of P-glycoprotein activity by nucleotide, nucleoside, and non-nucleoside reverse transcriptase inhibitors. <i>European Journal of Pharmacology</i> , 2008, 579, 104-109.	3.5	49
306	Prevention of intravenous drug incompatibilities in an intensive care unit. <i>American Journal of Health-System Pharmacy</i> , 2008, 65, 1834-1840.	1.0	62

#	ARTICLE	IF	CITATIONS
307	Cation exchange resins as pharmaceutical carriers for methylene blue: Binding and release. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2008, 69, 582-587.	4.3	20
308	Characteristics of Effective Electronic Mail Messages Distributed to Healthcare Professionals in a Hospital Setting. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2008, 15, 235-239.	4.4	3
309	Pharmacokinetics, Tissue Concentrations, and Safety of the Antifungal Agent Voriconazole in Chickens. , 2008, 22, 199-207.		29
310	Inhibition of Voriconazole Metabolism by Chloramphenicol in an Adolescent with Central Nervous System Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 4172-4174.	3.2	14
311	Voriconazole Concentration in Human Aqueous Humor and Plasma during Topical or Combined Topical and Systemic Administration for Fungal Keratitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 239-244.	3.2	115
312	Significant Pharmacokinetic and Pharmacodynamic Interaction of Warfarin With the NO-independent sGC Activator HMR1766. <i>Journal of Clinical Pharmacology</i> , 2007, 47, 70-77.	2.0	18
313	Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by Nucleoside, Nucleotide, and Non-Nucleoside Reverse Transcriptase Inhibitors. <i>Drug Metabolism and Disposition</i> , 2007, 35, 340-344.	3.3	125
314	Localization of the Human Breast Cancer Resistance Protein (BCRP/ABCG2) in Lipid Rafts/Caveolae and Modulation of Its Activity by Cholesterol in Vitro. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 323, 257-264.	2.5	118
315	Monitoring of lopinavir and ritonavir in peripheral blood mononuclear cells, plasma, and ultrafiltrate using a selective and highly sensitive LC/MS/MS assay. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 850, 249-258.	2.3	41
316	Electrospray tandem mass spectroscopic characterisation of 18 antiretroviral drugs and simultaneous quantification of 12 antiretrovirals in plasma. <i>Rapid Communications in Mass Spectrometry</i> , 2007, 21, 2704-2716.	1.5	55
317	Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. <i>Biochemical Pharmacology</i> , 2007, 73, 1573-1581.	4.4	136
318	Plasma LDL cholesterol has no impact on P-glycoprotein (MDR1/ABCB1) activity in human peripheral blood mononuclear cells. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2007, 376, 135-143.	3.0	10
319	Management of potential drug interactions in community pharmacies: a questionnaire-based survey in Switzerland. <i>European Journal of Clinical Pharmacology</i> , 2007, 63, 297-305.	1.9	21
320	NKIM-6, a new immortalized human brain capillary endothelial cell line with conserved endothelial characteristics. <i>Cell and Tissue Research</i> , 2007, 328, 19-29.	2.9	20
321	Drug-drug interactions with levodopa modulating treatment responses in Parkinson's disease. <i>Journal of Neurology</i> , 2007, 254, IV29-IV36.	3.6	5
322	Kinetics and dynamics of the peripheral neurokinin-1 receptor antagonist SLV317 in healthy individuals. <i>British Journal of Clinical Pharmacology</i> , 2006, 61, 414-419.	2.4	5
323	Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 126-135.	4.7	143
324	Pharmacokinetics of a netilmicin loading dose on the first postnatal day in preterm neonates with very w gestational age. <i>European Journal of Clinical Pharmacology</i> , 2006, 62, 773-777.	1.9	7

#	ARTICLE	IF	CITATIONS
325	Interaction of the mitotic kinesin Eg5 inhibitor monastrol with P-glycoprotein. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2006, 372, 291-299.	3.0	65
326	A similarity measure for case based reasoning modeling with temporal abstraction based on cross-correlation. <i>Computer Methods and Programs in Biomedicine</i> , 2006, 81, 41-48.	4.7	17
327	Fluconazole dosing in continuous veno-venous haemofiltration (CVVHF): need for a high daily dose of 800 mg. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 1019-1023.	0.7	48
328	EVALUATION OF INHIBITORY POTENCIES FOR COMPOUNDS INHIBITING P-GLYCOPROTEIN BUT WITHOUT MAXIMUM EFFECTS: F2 VALUES. <i>Drug Metabolism and Disposition</i> , 2006, 34, 203-207.	3.3	36
329	Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 59, 238-245.	3.0	173
330	Forearm blood flow responses in carriers of genetic polymorphisms of the NO pathway. <i>FASEB Journal</i> , 2006, 20, A289.	0.5	0
331	Fluvoxamine Affects Sildenafil Kinetics and Dynamics. <i>Journal of Clinical Psychopharmacology</i> , 2005, 25, 589-592.	1.4	12
332	Analysis of methylene blue in human urine by capillary electrophoresis. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2005, 826, 244-251.	2.3	27
333	Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 78, 25-33.	4.7	130
334	Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. <i>Biochemical Pharmacology</i> , 2005, 70, 949-958.	4.4	248
335	Dose individualisation in patients with renal insufficiency: does drug labelling support optimal management?. <i>European Journal of Clinical Pharmacology</i> , 2005, 60, 807-811.	1.9	27
336	Cytochrome P450 enzyme-mediated drug metabolism at exposure to acute hypoxia (corresponding to Tj ETQq 0.0,rgBT /Overlock 10	1.9	25
337	Information deficits in the summary of product characteristics preclude an optimal management of drug interactions: a comparison with evidence from the literature. <i>European Journal of Clinical Pharmacology</i> , 2005, 61, 327-335.	1.9	67
338	Modulation of endothelial and smooth muscle function by bed rest and hypoenergetic, low-fat nutrition. <i>Journal of Applied Physiology</i> , 2005, 99, 2196-2203.	2.5	29
339	INTERACTION OF PROGESTINS WITH THE HUMAN MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2 (MRP2). <i>Drug Metabolism and Disposition</i> , 2005, 33, 1576-1579.	3.3	28
340	Hypoxia Impairs Systemic Endothelial Function in Individuals Prone to High-Altitude Pulmonary Edema. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005, 172, 763-767.	5.6	132
341	In Vitro Assessment of Methylene Blue on Chloroquine-Sensitive and -Resistant Plasmodium falciparum Strains Reveals Synergistic Action with Artemisinins. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 4592-4597.	3.2	99
342	Drug interactions and risk of acute bleeding leading to hospitalisation or death in patients with chronic atrial fibrillation treated with warfarin. <i>Thrombosis and Haemostasis</i> , 2005, 94, 537-543.	3.4	73

#	ARTICLE	IF	CITATIONS
343	Autosomal-Dominant Hypertension With Type E Brachydactyly Is Caused by Rearrangement on the Short Arm of Chromosome 12. <i>Hypertension</i> , 2004, 43, 471-476.	2.7	35
344	Modulation of Cellular Cholesterol Alters P-Glycoprotein Activity in Multidrug-Resistant Cells. <i>Molecular Pharmacology</i> , 2004, 66, 1332-1339.	2.3	108
345	Oral Contraception Does Not Alter Single Dose Saquinavir Pharmacokinetics in Women. <i>British Journal of Clinical Pharmacology</i> , 2004, 57, 244-252.	2.4	25
346	Endothelial venodilator response in carriers of genetic polymorphisms involved in NO synthesis and degradation. <i>British Journal of Clinical Pharmacology</i> , 2004, 58, 169-177.	2.4	20
347	Association of the CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokinetics. <i>British Journal of Clinical Pharmacology</i> , 2004, 58, 443-444.	2.4	51
348	Undeclared exposure to St. John's Wort in hospitalized patients. <i>British Journal of Clinical Pharmacology</i> , 2004, 58, 437-441.	2.4	36
349	Influence of lipid lowering fibrates on P-glycoprotein activity in vitro. <i>Biochemical Pharmacology</i> , 2004, 67, 285-292.	4.4	37
350	In vitro and ex vivo evidence for modulation of P-glycoprotein activity by progestins. <i>Biochemical Pharmacology</i> , 2004, 68, 2409-2416.	4.4	89
351	A Drug Database Model as a Central Element for Computer-Supported Dose Adjustment within a CPOE System. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2004, 11, 427-432.	4.4	23
352	High prevalence of unknown co-medication in hospitalised patients. <i>European Journal of Clinical Pharmacology</i> , 2004, 60, 363-8.	1.9	16
353	Requirements for a successful implementation of drug interaction information systems in general practice: results of a questionnaire survey in Germany. <i>European Journal of Clinical Pharmacology</i> , 2004, 60, 595-602.	1.9	33
354	Pharmacokinetic interaction of chloroquine and methylene blue combination against malaria. <i>European Journal of Clinical Pharmacology</i> , 2004, 60, 709-715.	1.9	73
355	Simultaneous determination of hypericin and hyperforin in human plasma with liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004, 813, 27-33.	2.3	15
356	Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers*1. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 73-84.	4.7	152
357	Drug interactions in primary care: Impact of a new algorithm on risk determination*1. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 85-96.	4.7	59
358	Reduction of Saquinavir Exposure by Coadministration of Loperamide. <i>Clinical Pharmacokinetics</i> , 2004, 43, 1015-1024.	3.5	8
359	Cholesterol modulates P-glycoprotein activity in human peripheral blood mononuclear cells. <i>Biochemical and Biophysical Research Communications</i> , 2004, 316, 705-711.	2.1	42
360	Inhibition of the human organic anion transporter 1 by the caffeine metabolite 1-methylxanthine. <i>Biochemical and Biophysical Research Communications</i> , 2004, 320, 90-94.	2.1	10

#	ARTICLE	IF	CITATIONS
361	Acute hyperhomocysteinemia decreases NO bioavailability in healthy adults. <i>Atherosclerosis</i> , 2004, 176, 337-344.	0.8	37
362	P-glycoprotein modulation by the designer drugs methylenedioxyamphetamine, methylenedioxyethylamphetamine and paramethoxyamphetamine. <i>Addiction Biology</i> , 2003, 8, 413-418.	2.6	24
363	Pharmacokinetic and pharmaceutic interaction between digoxin and Cremophor RH40. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 73, 397-405.	4.7	86
364	Impact of serum creatinine measurement error on dose adjustment in renal failure. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 74, 458-467.	4.7	3
365	Interaction of ibuprofen and probenecid with drug metabolizing enzyme phenotyping procedures using caffeine as the probe drug. <i>British Journal of Clinical Pharmacology</i> , 2003, 55, 191-198.	2.4	12
366	Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction. <i>British Journal of Clinical Pharmacology</i> , 2003, 56, 32-38.	2.4	126
367	Quality of drug information on the World Wide Web and strategies to improve pages with poor information quality. An intervention study on pages about sildenafil. <i>British Journal of Clinical Pharmacology</i> , 2003, 57, 80-85.	2.4	26
368	Genotyping of the A6986G polymorphism of CYP3A5. <i>British Journal of Clinical Pharmacology</i> , 2003, 57, 663-663.	2.4	2
369	Highly sensitive determination of saquinavir in biological samples using liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2003, 784, 233-242.	2.3	19
370	Interaction of Antiepileptic Drugs with Human P-Glycoprotein in Vitro. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 307, 262-267.	2.5	129
371	Inhibition of P-Glycoprotein by Newer Antidepressants. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 305, 197-204.	2.5	278
372	Lack of Evidence for Association of High Altitude Pulmonary Edema and Polymorphisms of the NO Pathway. <i>High Altitude Medicine and Biology</i> , 2003, 4, 355-366.	0.9	32
373	Rapid and Reliable Genotyping of the C181T Polymorphism in the Bradykinin B2 Receptor Gene. <i>Clinical Chemistry and Laboratory Medicine</i> , 2003, 41, 281-3.	2.3	0
374	Rapid Detection of Polymorphisms of the Nitric Oxide Cascade. <i>Clinical Chemistry and Laboratory Medicine</i> , 2002, 40, 341-4.	2.3	6
375	Quality markers of drug information on the internet: an evaluation of sites about St. John's Wort. <i>American Journal of Medicine</i> , 2002, 113, 740-745.	1.5	43
376	Dose-dependent increase of saquinavir bioavailability by the pharmaceutic aid cremophor EL. <i>British Journal of Clinical Pharmacology</i> , 2002, 53, 576-581.	2.4	75
377	Poor solubility limiting significance of in-vitro studies with HIV protease inhibitors. <i>Aids</i> , 2002, 16, 674-676.	2.2	16
378	Drug dosage in patients with renal failure optimized by immediate concurrent feedback. <i>Journal of General Internal Medicine</i> , 2001, 16, 369-375.	2.6	76

#	ARTICLE	IF	CITATIONS
379	Local effect of transdermal isosorbide dinitrate ointment on hand vein diameter. <i>European Journal of Clinical Pharmacology</i> , 2001, 57, 701-704.	1.9	11
380	Risk of Cataract in Patients Treated With Statins. <i>Archives of Internal Medicine</i> , 2001, 161, 2021.	3.8	67
381	Auditory and electroencephalographic effects of midazolam and <i>4-hydroxy</i> midazolam in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2000, 49, 72-79.	2.4	46
382	Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine. <i>British Journal of Clinical Pharmacology</i> , 2000, 50, 237-246.	2.4	69
383	The mechanism of cryoinjury: In vitro studies on human internal mammary arteries. <i>British Journal of Pharmacology</i> , 2000, 130, 636-640.	5.4	13
384	Overconsumption detected by electronic drug monitoring requires subtle interpretation. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 67, 44-47.	4.7	19
385	Correlation between apolipoprotein B and endothelin-1-induced vasoconstriction in humans. <i>Peptides</i> , 2000, 21, 871-874.	2.4	8
386	Isoniazid plus Sulphadoxine-Pyrimethamine Can Reduce Morbidity of HIV-Positive Patients Treated for Tuberculosis in Africa: A Controlled Clinical Trial. <i>Chemotherapy</i> , 1999, 45, 452-465.	1.6	29
387	Neurokinin-1 receptor antagonist R116301 inhibits substance P-induced venodilation. <i>Clinical Pharmacology and Therapeutics</i> , 1999, 66, 522-527.	4.7	11
388	Academic detailing improves identification and reporting of adverse drug events. <i>International Journal of Clinical Pharmacy</i> , 1999, 21, 110-115.	1.4	35
389	Pharmacokinetics and pharmacodynamics of clomethiazole after oral and rectal administration in healthy subjects. <i>Clinical Therapeutics</i> , 1999, 21, 829-840.	2.5	9
390	Circulating cell adhesion molecules and endothelial markers before and after transluminal angioplasty in peripheral arterial occlusive disease. <i>Atherosclerosis</i> , 1999, 142, 193-200.	0.8	86
391	Rhabdomyolysis due to interaction of simvastatin with mibefradil. <i>Lancet, The</i> , 1998, 351, 1929-1930.	13.7	118
392	Acetaminophen is an inhibitor of hepatic N-acetyltransferase 2 in vitro and in vivo. <i>Pharmacogenetics and Genomics</i> , 1998, 8, 553-560.	5.7	23
393	Functional Activity of Bronchi from an Organ Donor with Fatal Asthma: Studies on Cryopreserved Bronchi. <i>Journal of Asthma</i> , 1998, 35, 179-186.	1.7	1
394	Safety and Efficacy of a Two-Compartment Bayesian Feedback Program for Therapeutic Tobramycin Monitoring in the Daily Clinical Use and Comparison With a Non-Bayesian One-Compartment Model. <i>Therapeutic Drug Monitoring</i> , 1998, 20, 172-180.	2.0	6
395	Moxonidine-induced cholestatic hepatitis. <i>Lancet, The</i> , 1997, 350, 1822.	13.7	9
396	Inverse correlation between endothelin-1-induced peripheral microvascular vasoconstriction and blood pressure in glaucoma patients. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 1997, 235, 634-638.	1.9	55

#	ARTICLE	IF	CITATIONS
397	Acute von Willebrand Factor Secretion from the Endothelium In Vivo: Assessment through Plasma Propeptide (vWf:AgII) Levels. <i>Thrombosis and Haemostasis</i> , 1997, 77, 387-393.	3.4	56
398	Quinaprilat Induces Arterial Vasodilation Mediated by Nitric Oxide in Humans. <i>Hypertension</i> , 1997, 30, 912-917.	2.7	31
399	Role of Nitric Oxide in the Regulation of the Mechanical Properties of Peripheral Conduit Arteries in Humans. <i>Hypertension</i> , 1997, 30, 1465-1470.	2.7	57
400	Vigabatrin dosing during haemodialysis. <i>Seizure: the Journal of the British Epilepsy Association</i> , 1996, 5, 239-242.	2.0	7
401	Clinical Pharmacists' Effect on Drug Information Requests. <i>Annals of Pharmacotherapy</i> , 1996, 30, 86-87.	1.9	0
402	N-Acetyltransferase 2 polymorphism in patients infected with human immunodeficiency virus. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 60, 62-67.	4.7	39
403	Substance P in human hand veins in vivo: Tolerance, efficacy, potency, and mechanism of venodilator action*. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 60, 435-443.	4.7	14
404	Low Whole-Blood $S$ -Adenosylmethionine and Correlation Between 5-Methyltetrahydrofolate and Homocysteine in Coronary Artery Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1996, 16, 727-733.	2.4	88
405	Subconstrictor Doses of Neuropeptide Y Potentiate $\beta_1$ -Adrenergic Venoconstriction In Vivo. <i>Hypertension</i> , 1996, 28, 483-487.	2.7	23
406	Neuropeptide Y in human hand veins: Pharmacologic characterization and interaction with cyclic guanosine monophosphate-dependent venodilators in vivo*. <i>Clinical Pharmacology and Therapeutics</i> , 1995, 58, 675-683.	4.7	8
407	Nitric Oxide Is Responsible for Flow-Dependent Dilatation of Human Peripheral Conduit Arteries In Vivo. <i>Circulation</i> , 1995, 91, 1314-1319.	1.6	1,326
408	Role of Basal and Stimulated Release of Nitric Oxide in the Regulation of Radial Artery Caliber in Humans. <i>Hypertension</i> , 1995, 26, 327-331.	2.7	62
409	Circadian Carbamazepine Toxicity. <i>Epilepsia</i> , 1994, 35, 400-402.	5.1	10
410	Glutathione S-transferase $\gamma$ polymorphism does not explain variation in nitroglycerin responsiveness. <i>Clinical Pharmacology and Therapeutics</i> , 1993, 53, 463-468.	4.7	15
411	Acyclovir-induced neurotoxicity: Concentration-side effect relationship in acyclovir overdose. <i>American Journal of Medicine</i> , 1993, 94, 212-215.	1.5	105
412	Evaluation of Conventional Chest Tube Therapy for Iatrogenic Pneumothorax. <i>Chest</i> , 1993, 104, 1770-1772.	0.8	22
413	Evidence for Activation of the Sympathetic Nervous System by Recombinant Human Interleukin-1 $\beta$ in Humans. <i>Journal of Immunotherapy</i> , 1993, 13, 136-140.	2.4	25
414	Comparison of vasodilatory responses to nitroglycerin and its dinitrate metabolites in human veins. <i>Clinical Pharmacology and Therapeutics</i> , 1992, 52, 590-596.	4.7	17



#	ARTICLE	IF	CITATIONS
415	Concentration-effect relations of 5-hydroxypropafenone in normal subjects. American Journal of Cardiology, 1991, 67, 1022-1026.	1.6	8
416	Potent Inhibition of Cytochrome P450IID6 (Debrisoquin 4-Hydroxylase) by Flecainide In Vitro and In Vivo. Journal of Cardiovascular Pharmacology, 1990, 15, 776-779.	1.9	41